A role of nitric oxide in WIN 55,212-2 tolerance in mice

European Journal of Pharmacology

Volumn 343, Issue 2-3, 1998, Pages 157-163

  Spina, Eleonora ^a   Trovati, Anna ^a   Parolaro, Daniela ^a   Giagnoni, Gabriella ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cannabinoid; Nitric oxide (NO); Tolerance

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID RECEPTOR AGONIST; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; CATALEPSY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG TOLERANCE; HYPOTHERMIA; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANALGESICS; ANIMALS; DRUG TOLERANCE; ENZYME INHIBITORS; MALE; MICE; MORPHOLINES; NAPHTHALENES; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0032545995     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01543-4     Document Type: Article

References (51)

1. 9-tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal. J. Pharmacol. Exp. Ther. 278:1996;1290-1295.
2. G-nitro-L-arginine methyl ester. Life Sci. 52:1993;245-249.
3. Babey A.M., Kolesnikov Y., Cheng J., Inturrisi C.E., Trifilletti R.R., Pasternak G.W. Nitric oxide and opioid tolerance. Neuropharmacology. 33:1994;1463-1470.
4. Barjavel M.J., Bhargava H.N. Effect of morphine tolerance and abstinence on nitric oxide synthase activity in brain regions and spinal cord of the mouse. Soc. Neurosci. Abstr. 20:1994;234.
5. Barjavel M.J., Bhargava H.N. Nitric oxide synthase activity in brain regions and spinal cord of mice and rats: Kinetic analysis. Pharmacology. 50:1995;168-174.
6. 9-tetrahydrocannabinol-induced hypothermia. Life Sci. 26:1980;845-850.
7. Bhargava H.N. Multiple opioid receptors of brain and spinal cord in opioid addiction. Gen. Pharmacol. 22:1991;767-772.
8. Bhargava H.N. Nitric oxide synthase inhibition blocks tolerance to the analgesic action of kappa-opiate receptor agonist in the rat. Pharmacology. 48:1994;234-241.
9. Bhargava H.N. Diversity of agents which modify opioid tolerance, physical dependence abstinence syndrome and self-administrative behavior. Pharmacol. Rev. 46:1994;293-324.
10. Bhargava H.N. Attenuation of tolerance to, and physical dependence on, morphine in the rat by inhibition of nitric oxide synthase. Gen. Pharmac. 26:1995;1049-1053.
11. 9-tetrahydrocannabinol in the mouse. Eur. J. Pharmacol. 68:1980;147-154.
12. 9-tetrahydrocannabinol in the mouse. Psychopharmacology. 57:1978;243-248.
13. Bloom, A.S., Hillard, C.J., 1985. Cannabinoids, neurotransmitters, receptors and brain membranes. In: Harvey, D.J. (Ed.), Marijuana 84. IRL Press, pp. 217-231.
14. Cappendijk S.L.T., De Vries R., Dzoljic M.R. Inhibitory effect of nitric oxide (NO) synthase inhibitors on naloxone-precipitated withdrawal syndrome in morphine-dependent mice. Neurosci. Lett. 162:1993;97-100.
15. Brignola G., Calignano A., Di Rosa M. Modulation of morphine antinociception in the mouse by endogenous nitric oxide. Br. J. Pharmacol. 113:1994;1372-1376.
16. Di Chiara G., North R.A. Neurobiology of opiate abuse. Trends Pharmacol. Sci. 13:1992;185-193.
17. Eddy N.B., Leimbach D. Synthetic analgesic (II): Diethyl-butenyl and dithienylbutylamines. J. Pharmacol. Exp. Ther. 107:1953;385-393.
18. G-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain. 56:1994;69-75.
19. 9-tetrahydrocannabinol. Br. J. Pharmacol. 75:1982;409-414.
20. Fukuto J.M., Chaudhuri G. Inhibition of constitutive and inducible nitric oxide synthase: Potential selective inhibition. Annu. Rev. Pharmacol. Toxicol. 35:1995;165-194.
21. Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci. 14:1991;60-67.
22. Herkenham, M., 1995. Localization of cannabinoid receptors in brain and periphery. In: Pertwee, R.G. (Ed.), Cannabinoid Receptors. Academic Press, London, pp. 145-165.
23. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA. 87:1990;1932-1936.
24. 9-tetrahydrocannabinol neurochemical and behavioral effects in the rat. Science. 163:1969;1464-1467.
25. Jacquet Y.F. The NMDA receptor: Central role in pain inhibition in rat periacqueductal gray. Eur. J. Pharmacol. 154:1988;271-276.
26. 9-tetrahydrocannabinol-tolerant rats. Psychopharmacology. 55:1977;243-249.
27. G-Nitro-L-arginine prevents morphine tolerance. Eur. J. Pharmacol. 221:1992;399-400.
28. Kolesnikov Y.A., Pick C.G., Ciszewska G., Pasternak G.W. Blockade of tolerance to morphine but not to κ-opioids by a nitric oxide synthase inhibitor. Proc. Natl. Acad. Sci. USA. 90:1993;5162-5166.
29. Lipa S.M., Kavaliers M. Sex differences in the inhibitory effects of the NMDA antagonist, MK-801, on morphine and stress-induced analgesia. Brain Res. Bull. 24:1990;627-630.
30. Mailleux P., Vanderhaeghen J.-J. Glutamatergic regulation of cannabinoid receptor gene expression in the caudate-putamen. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 266:1994;193-196.
31. Marek P., Ben-Eliyahu S., Gold M., Liebeskind J.C. Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res. 547:1991;77-81.
32. Martin B.R. Cellular effects of cannabinoids. Pharmacol. Rev. 38:1986;45-74.
33. G-Nitro-arginine methyl ester exhibits antinociceptive activity in the mouse. Br. J. Pharmacol. 102:1991;198-202.
34. Moore P.K., Wallace P., Gaffen Z., Hart S.L., Babbedge R.C. 7-Nitro-indazole, an inhibitor of nitric oxide synthase, exhibits anti-nociceptive activity in the mouse without increasing blood pressure. Br. J. Pharmacol. 108:1993;296-297.
35. Moore P.K., Wallace P., Gaffen Z., Hart S.L., Babbedge R.C. Characterization of the novel nitric oxide synthase inhibitor 7-nitro-indazole and related indazoles: Antinociceptive and cardiovascular effects. Br. J. Pharmacol. 110:1993;219-224.
36. G-nitro-arginine methyl ester-induced antinociception in mice: A role for serotonergic and adrenergic neurons. Gen. Pharmacol. 6:1992;1177-1182.
37. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 6:1992;3051-3064.
38. Pertwee R.G. The ring test: A quantitative method for assessing the 'cataleptic' effect of cannabis in mice. Br. J. Pharmacol. 46:1972;753-763.
39. Pertwee R.G. The central neuropharmacology of psychotropic cannabinoids. Pharmacol. Ther. 36:1988;189-261.
40. Przewlocki R., Machelska H., Przewlocka B. Inhibition of nitric oxide synthase enhances morphine antinociception in the rat spinal cord. Life Sci. 53:1993;PL1.
41. Przewlocki R., Machelska H., Przewlocka B. Modulation of morphine and cocaine effects by inhibition of nitric oxide synthase. Regul. Pept. 54:1994;233-235.
42. ω-nitro-L-arginine (L-NA) and its methyl ester (L-NAME). Neuropharmacology. 34:1995;639-649.
43. Snyder S.H., Bredt D.S. Nitric oxide as a neuronal messenger. Trends Pharmacol. Sci. 12:1991;125-128.
44. Steel, R.G., Torrie, J.H., 1960. Principles and Procedures of Statistics. McGraw-Hill Book Company New York.
45. 9-tetrahydrocannabinol in mice. Eur. J. Pharmacol. 260:1994;5-13.
46. 9-tetrahydrocannabinol in mice. Brain Res. 667:1994;77-82.
47. Thorat S.N., Reddy P.L., Bhargava H.N. Evidence for the role of nitric oxide in κ-opiate tolerance to the analgesic action of κ-opiate receptor agonists in the rat. Brain Res. 621:1993;171-174.
48. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 251:1991;85-87.
49. 9-tetrahydrocannabinol in rats. Eur. J. Pharmacol. 70:1981;219-224.
50. Vaupel D.B., Kimes A.S., London E.D. Comparison of 7-nitroindazole with other nitric oxide synthase inhibitors as attenuators of opioid withdrawal. Psycopharmacology. 118:1995;361-368.
51. Welch S.P., Stevens D.L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther. 262:1992;10-18.